Trial Evaluating the Tailored Versus the Systematic Use of Defunctioning Stoma After Total Mesorectal Excision for Rectal Cancer (GRECCAR17)

GRECCAR 17 will be the first prospective and randomized trial to assess a tailored policy in the use of defunctioning stoma after TME according to the personalized risk of anastomotic leakage. The tailored use of defunctioning stoma after TME for rectal cancer should improve both the quality of life of patients and the anorectal function, without any impact on anastomotic leakage. Moreover, for the healthcare system, this new approach could be a cost-effective strategy, leading to a decrease in healthcare expenses. The main objective is to compare the impact of tailored defunctioning stoma af

Trial Details

NCT ID
NCT05233787
Phase
NA
Sponsor
University Hospital, Bordeaux
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Tailored use of defunctioning stoma after TME
  • Systematic use of defunctioning stoma
Locations (sample)
  • Amiens, France|49.9,2.3
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Bordeaux, France|44.84124,-0.58046
  • Clermont-Ferrand, France|45.77969,3.08682

Key Eligibility Criteria

  • Age 18-80 years;
  • Rectal adenocarcinoma (histologically proven)
  • No metastasis or medical history of colorectal metastasis (M0)
  • Patients with rectal cancer \< 12 cm from the anal verge (determined by rectal examination or MRI)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →